Product overview

Name Sipatrigine
Alternative names 619C89
Purity >98%
Description Na+ / Ca+ channel blocker
Write Your Own Review
You're reviewing:Sipatrigine
Rate this item:

Biological Data

Biological description Na+, Ca+ channel blocker (IC50 = 10 µM for R type Ca2+ channel currents). Also acts as TREK-1 antagonist and inhibits glutamate release. Analog of lamotrigine. Displays neuroprotective and antidepressant properties.

Solubility & Handling

Storage instructions Room temperature
Solubility overview Soluble in DMSO (100mM) or ethanol (25mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use



More Info


More Info

Chemical Data

Purity >98%
Chemical name 2-(4-Methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinamine
Molecular Weight 372.68
Chemical structure Sipatrigine  [130800-90-7] Chemical Structure
Molecular Formula C15H16Cl3N5
CAS Number 130800-90-7
PubChem identifier 60803
InChi InChI=1S/C15H16Cl3N5/c1-22-2-4-23(5-3-22)15-20-8-11(14(19)21-15)10-6-9(16)7-12(17)13(10)18/h6-8H,2-5H2,1H3,(H2,19,20,21)
MDL number MFCD00867772

References for Sipatrigine

References are publications that support the biological activity of the product
  • Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1.

    Tsai SJ (2008) Med Hypotheses 70(3) : 548-50.
  • The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential.

    Gao Z et al (2005) Clin Exp Pharmacol Physiol 32(12) : 1088-96.
  • Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents.

    Hainsworth AH et al (2003) Eur J Pharmacol 467(1-3) : 77-80.
  • BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage.

    Leach MJ et al (1993) Stroke 24(7) : 1063-7.

4 Item(s)